Disease & Vaccine Information

Please select disease or vaccine
Ask 8 Information Kiosk

Explore FREE downloadable educational materials.

Connect with us!

Report Your Vaccine Experiences

Read and report vaccine reactions, harassment and failures. 

Hib disease and vaccine quick facts

Quick Facts About Haemophilus Influenzae Type B (Hib)

Haemophilus Influenzae Type B (Hib)

  • Haemophilus influenzae type b (Hib) is a bacterial infection that can cause severe illnesses in children, including meningitis, epiglottitis, pneumonia, arthritis, and cellulitis; 
  • Hib meningitis, an infection of the membranes covering the brain and one of the most serious complications of Hib, may occur following an upper respiratory illness. Infection can spread from the sinuses and lungs into the bloodstream and to the brain causing meningitis; 
  • Hib is spread through person-to-person transmission, mostly through the air. It is often found in the respiratory tracts of adults with no noted symptoms or adverse effects.  Hib must enter into the bloodstream for it to cause meningitis or other forms of invasive disease; 
  • Hib infection more frequently occurs in infants and children under the age of 5. Other high-risk populations can include Alaska Natives, American Indians, adults 65 years of age and older, and persons with certain medical conditions, including immunosuppression; 
  • In general, the transmission of Hib is considered to be limited and when it occurs, it usually affects only close contacts such as household members.   Prior to the introduction of the Hib vaccine, most children acquired natural immunity to Hib by the time they were 5 or 6 years old. 

 Hib Vaccine

  • There are currently four different Haemophilus influenzae type b (Hib) vaccines available for use in the United States. These four vaccines are: ActHIB; Hiberix; PedvaxHIB; and Pentacel (Hib vaccine combined with diphtheria and tetanus toxoids, acellular pertussis adsorbed, and inactivated poliovirus).  The CDC recommends infants receive Hib vaccine at 2, 4, and 6 months of age with an additional booster dose between 12 and 15 months of age. Hib vaccine is also recommended by the CDC for use in older children, adolescents and adults with certain medical conditions,  however, no Hib vaccines are FDA approved for use in persons over five years of age.  On December 21st, 2018, the FDA approved VAXELIS, a 6 in 1 combination vaccine containing diphtheria and tetanus toxoids, acellular pertussis adsorbed, inactivated poliovirus, hepatitis B recombinant, and Hib conjugate vaccine.  VAXELIS is expected to be available for use in the United States in 2020,  however, at this time the CDC’s Advisory Committee on Immunization Practice (ACIP) has not made any recommendations regarding the use of VAXELIS.
  • Mild side effects such as redness, warmth, or swelling where the shot was given have been reported in connection with administration of Hib vaccines.  Systemic reactions, such as fever and irritability can also occur.  Severe reactions involving Hib vaccination reported during pre-licensing clinical trials and currently continue to be reported to the Vaccine Adverse Events Reporting System (VAERS) include deaths, anaphylactic reaction, asthma, pneumonia, convulsions, noninfectious encephalitis, acute pancreatitis, peripheral neuropathy, Guillain-Barre syndrome, sepsis, seizures, and cerebral edema.     
  • All infants and children who participated in Hib vaccine pre-licensing clinical trials also received other vaccines in addition to the Hib vaccine. As a result, it is not possible to determine the specific adverse reaction to monitor for following Hib vaccination.      The administration of multiple vaccines also makes it difficult to determine the specific vaccine that might have triggered the reactions reported in both clinical studies and to VAERS.
  • Using the MedAlerts search engine, as of March 31, 2023, there have been more than 90,507 reports of Hib vaccine reactions, hospitalizations, injuries and deaths following Hib vaccinations made to the federal Vaccine Adverse Events Reporting System (VAERS), including 2,882 related deaths, 18,515 hospitalizations, and 1,813 related disabilities. Nearly 85 percent of HIB vaccine-related adverse events occurred in children three years old and under. Of these Hib-vaccine related deaths reported to VAERS, nearly 92 percent of the deaths occurred in children under three years of age. Of these reported deaths, 2,149 occurred in infants under the age of 6 months.
  • As of April 1, 2023, there had been 175 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following HIB vaccination, including 33 deaths and 142 serious injuries.

Food & Drug Administration (FDA)

Centers for Disease Control (CDC)

Vaccine Reaction Symptoms & Ingredients

Our Ask 8, If You Vaccinate webpage contains vaccine reaction symptoms and more. 

Search for Vaccine Reactions 

NVIC hosts MedAlerts, a powerful VAERS database search engine. MedAlerts examines symptoms, reactions, vaccines, dates, places, and more.

Reporting a Vaccine Reaction

Since 1982 the NVIC has operated a Vaccine Reaction Registry, which has served as a watchdog on VAERS. Reporting vaccine reactions to VAERS is the law. If your doctor will not report a reaction, you have the right to report a suspected vaccine reaction to VAERS.

IMPORTANT NOTE: NVIC encourages you to become fully informed about Haemophilus Influenzae Type B (Hib) and the Hib vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.



Opens in new tab, window
Opens an external site
Opens an external site in new tab, window